Association Between Vitamin D Deficiency and Adrenal Gland, Kidney Function, Indicators Related to Cardiovascular Function in Hypertensive Patients

Why It Matters

The findings suggest vitamin D status may influence both endocrine drivers of hypertension and renal health, highlighting a potential modifiable risk factor for cardiovascular and kidney outcomes in hypertensive populations.

Key Takeaways

• 165 of 250 hypertensive patients (66%) were vitamin D deficient.
• Deficient group showed higher aldosterone, ARR, and serum sodium levels.
• Primary aldosteronism odds 79% lower with sufficient vitamin D (OR 0.21).
• Lower 25‑OH‑D linked to reduced eGFR, indicating renal impairment.
• CKD patients had larger left atrial and pulmonary artery diameters.

Pulse Analysis

Vitamin D deficiency has long been associated with skeletal disorders, yet its role in cardiovascular and renal physiology is gaining attention. In hypertensive cohorts, low 25‑hydroxyvitamin D levels often coexist with metabolic derangements that exacerbate blood pressure control. Recent research from a Chinese PLA General Hospital cardiology unit underscores this link, revealing that two‑thirds of hospitalized hypertensive patients were deficient, a prevalence that mirrors global trends in urban populations. The deficiency correlates with electrolyte imbalances and heightened aldosterone activity, suggesting a broader endocrine disruption beyond bone health.

The study’s statistical analyses provide compelling evidence that vitamin D status is not merely a by‑product of hypertension but may actively contribute to its pathogenesis. Patients with sufficient vitamin D had markedly lower odds of primary aldosteronism, a condition that drives resistant hypertension through excess mineralocorticoid production. Moreover, an inverse relationship between serum 25‑OH‑D and eGFR indicates that deficiency could accelerate renal function decline, a critical concern given the bidirectional relationship between kidney disease and blood pressure elevation. Notably, individuals with chronic kidney disease exhibited structural cardiac changes, such as enlarged left atrial dimensions, which are predictive of adverse cardiovascular events.

Clinicians should consider routine vitamin D screening for hypertensive patients, especially those with unexplained aldosterone excess or early signs of renal impairment. Supplementation strategies, tailored to achieve serum levels above 50 nmol/L, might improve endocrine balance and preserve kidney function, though randomized trials are needed to confirm causality. Integrating vitamin D assessment into hypertension management protocols could enhance risk stratification and open avenues for adjunctive therapy, ultimately reducing the burden of cardiovascular and renal complications.